AP - Regulators ended last week and started this one by rejecting two potential blockbuster cholesterol drugs, leaving three drugmakers reeling and Wall Street wondering if tougher approval standards are here.
This entry was posted
on Tuesday, April 29th, 2008 at 6:59 pm and is filed under Cholesterol.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
